Hypochondroplasia clinical trials at UCSF

5 in progress, 2 open to eligible people

Hypochondroplasia is a genetic bone growth condition that results in short stature and short arms and legs. UCSF is recording height, growth rates, and clinical details from children to document their health over years. UCSF is enrolling children 2.5 to under 17 years old in long-term non-interventional studies.

Showing trials for

  • Multinational Observational Study of Children With Hypochondroplasia

    open to eligible people ages up to 15 years

    This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

    Oakland, California and other locations

  • Clinical Assessment Study in Children With Hypochondroplasia

    open to eligible people ages 30 months to 16 years

    This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).

    Oakland, California and other locations

  • Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to < 36 months over a 52-week period.

    Oakland, California and other locations

  • Interventional Study of Infigratinib in Children With Hypochondroplasia

    Sorry, accepting new patients by invitation only

    ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety, of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib, at one of two doses, of who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).

    Oakland, California and other locations

  • Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

    Sorry, accepting new patients by invitation only

    Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.

    Oakland, California and other locations

Last updated: